153 267

Cited 40 times in

High Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients with Advanced Non–Small Cell Lung Cancer on Platinum-Based Combination Chemotherapy

 Kyung-Hun Lee  ;  Se-Hoon Lee  ;  Dong-Wan Kim  ;  Won Jun Kang  ;  June-Key Chung  ;  Seock-Ah Im  ;  Tae-You Kim  ;  Young Whan Kim  ;  Yung-Jue Bang  ;  Dae Seog Heo 
 CLINICAL CANCER RESEARCH, Vol.12(14 Pt 1) : 4232-4236, 2006 
Journal Title
Issue Date
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Carcinoma, Non-Small-Cell Lung/diagnosis* ; Carcinoma, Non-Small-Cell Lung/diagnostic imaging* ; Cisplatin/administration & dosage* ; Female ; Fluorodeoxyglucose F18/pharmacokinetics* ; Humans ; Lung Neoplasms/diagnosis* ; Lung Neoplasms/diagnostic imaging* ; Male ; Middle Aged ; Positron-Emission Tomography/methods* ; Radiopharmaceuticals* ; Retrospective Studies ; Time Factors ; Treatment Outcome
PURPOSE: To evaluate response and survival for platinum-based combination chemotherapy in chemonaive patients with non-small cell lung cancer (NSCLC) according to pretreatment standardized uptake values (SUV) by fluorodeoxyglucose positron emission tomography. EXPERIMENTAL DESIGN: Patients with advanced NSCLC who had not previously received chemotherapy were eligible. Response rates and survivals were analyzed according to maximal SUVs [low (<or=7.5) versus high (>7.5), where 7.5 was the median value] before the first cycle of chemotherapy. RESULTS: Eighty-five consecutive patients were included in the retrospective study. Patients with high SUV tumors exhibited significantly higher response rates (34.1% for low SUVs versus 61.0% for high SUVs; P = 0.013). Other factors, including sex, age, histology, performance status, number of involved organs, regimens used, and disease stage, did not affect response. However, high SUVs were related with a shorter response duration (279 days for low SUVs versus 141 days for high SUVs; P = 0.003) and time to progression (282 days for low SUVs versus 169 days for high SUVs; P = 0.015). Overall survival was unaffected by maximal SUVs (623 days for low SUVs versus 464 days for high SUVs; P = 0.431). CONCLUSIONS: Patients having NSCLC with high maximal SUVs showed a better response to platinum-based combination chemotherapy but had a shorter time to progression. Tumor glucose metabolism, as determined by SUVs on fluorodeoxyglucose positron emission tomography, was found to discriminate NSCLC subsets with different clinical and biological features.
Files in This Item:
T200604536.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers
Yonsei Authors
Kang, Won Jun(강원준) ORCID logo https://orcid.org/0000-0002-2107-8160
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.